Continue Daridorexant with Enhanced Monitoring
In a patient with fleeting suicidal ideation assessed as low risk, daridorexant (Quviviq) does not need to be discontinued, but requires close monitoring for worsening psychiatric symptoms. The FDA label does not list suicidal ideation as a contraindication or black box warning for daridorexant, unlike low-dose doxepin where this risk cannot be excluded 1.
Key Clinical Reasoning
Why Continuation is Appropriate
The FDA labeling for daridorexant does not identify suicidal ideation or psychiatric comorbidity as contraindications 2. This contrasts sharply with the insomnia guideline's explicit statement that "low-dose doxepin has no black box warning for suicide risk, but the risk for suicidal ideation associated with use of low-dose doxepin as a hypnotic agent is unknown and cannot be excluded" 1. The absence of such warnings for daridorexant is clinically meaningful.
Real-world evidence supports safety in psychiatric populations. A 2024 naturalistic study specifically examined daridorexant 50 mg in 66 patients with insomnia and comorbid mental disturbances, including 64% with unipolar/bipolar depression, anxiety disorders, and substance use disorders 3. Critically, the Suicidal Ideation Scale scores significantly decreased over 3 months of treatment (p < 0.001), suggesting daridorexant may actually improve suicidal ideation by treating the underlying insomnia 3.
Monitoring Protocol
Since the patient was started today, implement this structured approach:
- Daily assessment for the first week: Check for worsening suicidal ideation, emergence of new psychiatric symptoms, or behavioral changes
- Specific safety concerns from FDA data: Monitor for next-morning impairment (statistically significant after first dose), postural instability if awakened mid-sleep (increased body sway at 4 hours post-dose), and memory impairment 2
- Week 2-4 monitoring: Transition to twice-weekly contact, assessing both insomnia improvement and psychiatric stability
- Beyond 1 month: Monthly follow-up if stable, as therapeutic effects plateau by month 1 and maintain through month 3 2
Clinical Pitfalls to Avoid
Do not abruptly discontinue based solely on pre-existing low-risk suicidal ideation. The 2025 VA/DoD suicide risk guidelines emphasize that there is insufficient evidence to recommend specific risk stratification tools, and management should focus on evidence-based interventions 4. Untreated insomnia itself increases suicide risk, making treatment continuation potentially protective.
Warn about next-morning driving impairment. The FDA driving simulator study showed statistically significant impairment 9 hours after dosing in both adult and elderly subjects after the first dose, though this improved after 4 consecutive nights 2. Individual variation exists, so counsel against driving until response is known.
Avoid combining with other CNS depressants initially. While a case report describes successful combination with low-dose quetiapine for subsyndromal delirium 5, start with monotherapy in your patient to assess tolerability and avoid compounding sedation risks.
When to Discontinue
Stop daridorexant if:
- Suicidal ideation escalates from fleeting to active with intent or plan
- New-onset complex sleep behaviors emerge (sleepwalking, sleep-driving per FDA safety announcement) 1
- Severe next-morning sedation interferes with functioning after 4-5 days
- Paradoxical worsening of insomnia or psychiatric decompensation
Alternative Consideration
If psychiatric concerns escalate despite monitoring, cognitive behavioral therapy for insomnia (CBT-I) remains the gold standard and is suggested for patients with recent suicidal behavior 4, 1. CBT-I can be offered alongside daridorexant or as replacement therapy, as it shows superior long-term outcomes compared to pharmacotherapy alone 1.